Harbour BioMed (HKG: 2142), a global biotechnology company with operations in the United States, the Netherlands, and Suzhou, China, has announced a strategic collaboration with China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269). Under the agreement, WuXi Biologics’ controlling subsidiary, WuXi Vaccines, will take over Harbour BioMed’s industrialization plant in Suzhou. Financial details of the transaction were not disclosed.
Collaboration Details
WuXi Biologics will provide integrated services to meet Harbour BioMed’s global pipeline development and manufacturing needs. This collaboration aims to leverage WuXi Biologics’ expertise in biologics development and manufacturing to support Harbour BioMed’s global pipeline, ensuring efficient and high-quality production capabilities.
Harbour BioMed’s Technology Platform
Harbour BioMed is known for its proprietary antibody technology platform, Harbour Mice, which enables the development of monoclonal antibodies (mAbs) in the form of H2L2 and HCAb. The company has also developed the HBICE immune cell connector based on the HCAb antibody platform. HBICE is designed to achieve anti-tumor effects that traditional drug combination therapies cannot match, offering a unique approach to cancer treatment.-Fineline Info & Tech
